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A fluorescence quenching assay to discriminate between specific
and nonspecific inhibitors of dengue virus protease
Abstract
In drug discovery, the occurrence of false positives is a major hurdle in the search for lead compounds
that can be developed into drugs. A small-molecular-weight compound that inhibits dengue virus
protease at low micromolar levels was identified in a screening campaign. Binding to the enzyme was
confirmed by isothermal titration calorimetry (ITC) and nuclear magnetic resonance (NMR). However,
a structure-activity relationship study that ensued did not yield more potent leads. To further
characterize the parental compound and its analogues, we developed a high-speed, low-cost, quantitative
fluorescence quenching assay. We observed that specific analogues quenched dengue protease
fluorescence and showed variation in IC(50) values. In contrast, nonspecifically binding compounds did
not quench its fluorescence and showed similar IC(50) values with steep dose-response curves. We
validated the assay using single Trp-to-Ala protease mutants and the competitive protease inhibitor
aprotinin. Specific compounds detected in the binding assay were further analyzed by competitive ITC,
NMR, and surface plasmon resonance, and the assay's utility in comparison with these biophysical
methods is discussed. The sensitivity of this assay makes it highly useful for hit finding and validation in
drug discovery. Furthermore, the technique can be readily adapted for studying other protein-ligand
interactions.
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ABSTRACT  
A small molecular weight compound that inhibits dengue virus (DENV) protease at low micro-molar 
levels was identified from follow-up studies in a screening campaign. Isothermal titration calorimetry 
(ITC) and nuclear magnetic resonance confirmed its binding to the enzyme. A structure-activity-
relationship study that ensued did not yield more potent leads. For better characterization, the parental 
compound and its analogues were tested against DENV types 1-4 and West Nile virus proteases. In 
order to discriminate between specific and non-specific inhibition, we developed a high-speed, low-cost, 
and quantitative fluorescence quenching assay. We observed that non-specifically binding compounds 
did not quench DENV protease fluorescence, and showed similar IC50 values with steep dose-response 
curves. In contrast, specific inhibitors quenched DENV protease fluorescence and showed variation in 
IC50 values. Specific compounds detected in the fluorescent binding assay were verified by competitive 
ITC and further analyzed by surface plasmon resonance. The utility of this fluorescence binding assay in 
comparison with other biophysical methods tested is discussed. The sensitivity of this binding assay 
makes it highly useful for hit-finding and hit-to-lead activities in drug discovery. 
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INTRODUCTION 
High throughput screening (HTS) is a major method in drug discovery for new small lead molecules. 
In high-throughput enzyme inhibition assays, over a million compounds are usually tested for their 
abilities to inactivate the target enzyme. Often, the process involves two consecutive screens(1, 2). The 
first screen identifies compounds that inhibit the enzymatic activity and is usually performed at a single 
compound concentration. The second screen confirms the positive hits from the former by measuring 
IC50 values i.e. the concentration of compound needed to obtain 50% inhibition of the enzyme in the in 
vitro assay. After the second round, one may still be left with hundreds of lead candidates, many of 
which could be false positives(3).  
Often one or more candidate lead compound classes are chosen as starting points for structure-activity 
relationship (SAR) studies. Compounds are chemically derivatized in order to improve their inhibitory 
capacity or IC50. IC50 measurements alone, however, contain no information on the inhibitory 
mechanism. It has been widely documented that an IC50 value can arise from many mechanisms beside 
specific inhibition such as target sequestration, compound aggregation or interference with the 
enzymatic assay(4). IC50 values may thus serve as a disqualifying parameter (if the compound is only 
weakly active) but should not be the only qualifying parameter for identification of a lead compound. 
It is crucial, therefore, to have additional screening methods in drug discovery to determine the 
specificity of a compound for the target in order to deliver high quality candidate compounds for lead 
generation. Since dozens of compounds are usually evaluated during hit confirmation and hit-to-lead 
chemistry, additional screening methods have to satisfy three requirements: (i) low cost (in terms of 
amounts of compound and protein needed), (ii) high throughput and (iii) the ability to identify specific 
binding. 
The best method to characterize inhibition mechanism is via enzyme kinetics studies. In general this 
cannot be done systematically since the throughput is very low and analyses of mechanisms of complex 
enzymes are challenging. Established biochemical methods to identify non-specific inhibitors include 
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the variation of enzyme concentrations and the addition of non-ionic detergent (such as triton-X-100) or 
bovine serum album (BSA) in the enzymatic assay(3). In particular, additives such as triton X-100 can 
discriminate specific from non-specific inhibitors that act via formation of colloidal aggregates(5, 6). 
Not all enzyme assays, however, tolerate triton-X-100, which is also not necessarily compatible with 
robotic screening platforms. In addition, as the promiscuous nature of some inhibitors depends on the 
protein target, this method cannot eliminate all false positives (3).  
Other known screening methods employ biophysical techniques to detect binding of compounds to the 
target enzyme. A compound with a good IC50 value often has a good binding affinity (or low 
dissociation constant KD)(7). Table 1 presents a non-exhaustive list of techniques used to measure 
binding. Isothermal titration calorimetry (ITC) is one of the best methods for binding studies as it yields 
binding and thermodynamic parameters that can be highly useful for guiding SAR and compound 
design(8). Despite the recent development of high-throughput and small-volume calorimeters, ITC 
remains a costly method in terms of quantity of protein needed.  
Nuclear magnetic resonance (NMR) spectroscopy and X-ray crystallography can yield very valuable 
structural information about the binding sites but requires too much protein and compound for 
acceptable throughput. ITC, NMR and crystallography also share the disadvantage of requiring 
compounds often at concentrations above 100 µM. As compounds used in drug discovery tend to be 
highly hydrophobic in nature they are frequently not very soluble at these concentrations in aqueous 
buffer, thereby limiting the types of compounds that can be analyzed by these methods. 
Surface plasmon resonance (SPR) could be a method of choice since good throughput is easily 
achievable(9). However, immobilized proteins may not retain their native characteristics. Finally, since 
proteins are stabilized by ligand binding, this effect can be measured by thermal denaturation 
experiments(10). Although the throughput of this method is good and costs are low, this technique does 
not assess specificity of binding as proteins may also be stabilized by non-specific ligands.  
This article reports the development of a selective and high-throughput binding assay in the context of 
anti-dengue drug discovery. Dengue virus (DENV) protease is an obvious target for anti-dengue drug 
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development(11, 12). It plays a key role in the replication of the virus by cleaving the viral polyprotein 
precursor after translation. The protease domain is contained in non-structural protein 3 (NS3)(13) and 
its activity is greatly enhanced by interactions with the NS2B protein which acts as its co-factor(14, 15). 
Several efforts to find inhibitors for different flavivirus proteases (West Nile virus (WNV), dengue and 
Yellow Fever) have been reported, with several studies focusing on peptidic substrate based 
inhibitors(16-21) while others identified non-peptidic inhibitors from in vitro screening (22-24) or in 
silico high-throughput docking(25). None of these compounds has the appropriate properties for drug 
development, either because the scaffold is too labile(19-21, 23) or the inhibitors bind too weakly(22, 
24). 
Our attempts to identify a non-peptidic inhibitor of dengue protease led to establishment of a simple 
and efficient binding assay based on tryptophan fluorescence as described herein. It provides 
quantitative compound binding affinities and identifies promiscuous inhibitors in an inexpensive way 
that is compatible with a high-throughput setup. 
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MATERIALS AND METHODS 
Chemistry. All compounds generated in Figure 1 were determined to have >95% purity by HPLC. See 
supplementary information. 
Materials. All compounds (1-9, Bz-nKRR-H) were chemically synthesized in-house. Fluorogenic 
peptide substrate Bz-Nle-Lys-Arg-Arg-AMC was purchased from LSU Health Sciences Center (New 
Orleans, LA) and bovine pancreatic trypsin inhibitor was purchased from Sigma-Aldrich (St Louis, MO). 
PCR was carried out using Turbo Pfu polymerase from Stratagene (La Jolla, CA). Restriction enzymes 
and modifying enzymes were purchased from New England Biolabs (Beverly, MA). Oligonucleotides 
were synthesized by Research Biolabs (Singapore).  
 
Cloning of DENV2 CF40-gly -NS3pro185 W mutant constructs. All W mutants were generated using 
overlapping PCR using the plasmid DENV2 TSV01 pET15b-CF40-gly-NS3pro185 as a template(26). 
To obtain cNS2B with W mutations, PCR was carried out using the forward primer NS2BcfXhoI-F (26) 
and reverse primers W5A-REV, W50A-REV, W69A-REV, W83A-REV and W89A-REV respectively 
(Supporting information Table S1). To obtain NS3pro185 with W mutations, PCR was carried out using 
the forward primers W5A-FOR, W50A-FOR, W69A-FOR, W83A-FOR, and W89A-FOR, respectively 
(Supporting information Table S1), and reverse primer NS3pro185BamHI-R(26). The two products 
were joined in the second round of PCR using the primer-pair NS2BcfXhoI-F and NS3pro185BamHI-R 
to generate the individual CF40-gly-NS3pro185 W mutants. The overlapped PCR products were 
digested with XhoI and BamHI, and ligated into the same sites in pET15b. 
 
Protein expression and purification. Expression and purification of DENV2 CF40-gly-NS3pro185 has 
been described previously(26). Briefly, E. coli BL21-CodonPlus(DE3)-RIL (Stratagene) transformed 
with these plasmids were grown in Luria-Bertani (LB) broth, supplemented with ampicillin (100 mg/ml) 
and chloramphenicol (50 mg/ml) at 37 oC until OD600 reached approximately 0.5. Protein expression 
was induced with 0.4 mM IPTG at 16 oC for 20 h. Cells were harvested by centrifugation and 
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resuspended in 4 ml of phosphate buffered saline, containing 1% Triton X-100 (PBT). Cells were lysed 
by sonication and debris removed by centrifugation at 35,000 rpm for 30 min. The resulting protein 
solution was filtered through a 0.22 µm filter and loaded onto a 5 ml HiTrap chelating HP (Amersham 
Biosciences, Piscataway, NJ) column equilibrated with lysis buffer. The resin was washed with 10 
column volumes lysis buffer before bound proteins were eluted from the column with lysis buffer and a 
linear gradient of imidazole from 20-300 mM in the same buffer. Peak fractions were analyzed by 10% 
SDS-PAGE. Positive fractions were pooled, desalted and concentrated with spin concentrators (Amicon 
Ultra-15ml, molecular weight cut-off 10,000 Da; Millipore, Billerica, MA).  
 
Enzymatic Assay. The assay has been described previously (18). Briefly, activities of cNS2B/NS3pro 
complexes were measured in a Safire2 plate reader (Tecan) (λexc = 385 nM; emission: λexc = 465 nM) and 
performed in a final volume of 50 µl containing 50 mM Tris/HCl, pH 7.5, 1 mM CHAPS, 20% glycerol 
and 50 µM Bz-Nle-Lys-Arg-Arg-AMC at 37 oC. Control reactions contained 50 nM of CF40-gly-
NS3pro185. The proteolytic reaction was monitored by an increase in fluorescence (RFU/min) which 
was subsequently converted to M·s-1 from a standard AMC calibration curve. Progression curves were 
fitted to Michaelis-Menten kinetics by nonlinear regression using GraphPad Prism. Steady-state kinetic 
constants of each substrate were determined from triplicate measurements and reported as mean ± 
Standard Error (SE). 
 
Inhibitors were assayed in a 96-well plate format using 50 mM Tris/HCl, pH 7.5, 1 mM CHAPS in a 
final volume of 50 µl. Typically, protease (40 nM) was pre-incubated with 0-100 µM concentrations of 
test compounds at 37 oC for 30 min. The reaction was initiated by the addition of 20 µM substrate Bz-
nKRR-AMC. Reaction progress was monitored continuously by following the increase in fluorescence 
on a Tecan Safire2 plate reader. IC50 values of inhibitors were derived by fitting the calculated initial 
velocities to a non-linear regression curve using GraphPad Prism software. Each point of the IC50 curve 
was measured in duplicate during a single experiment. 
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Buffer. The buffer used for absorbance spectra, titration, and ITC was 50 mM Tris/HCl, pH 7.5, 50 
mM NaCl. 
 
Absorbance Spectra. Absorbance spectra of compounds were measured on a Tecan Safire2. All 
compounds were diluted in 90 µl buffer to a final concentration of 100 µM on a UV-star 96-well 
microplate (Greiner). 
 
Fluorescence-monitored Titrations. Two protein solutions were prepared (2-5 µM protein with and 
without 40 µM compound) and were mixed in a microplate to obtain 12 different compound 
concentrations ranging from 0-40 µM in about 3.5 µM steps. 90 µl of each dilution were thereafter 
transferred to a UV-star Greiner microplate 96-wells. After 1 h incubation at room temperature, 
fluorescence was measured at 25 oC on a Tecan Safire2 with λexc=280 nm and λem=340 nm. The setting 
for slit widths depended on the protein concentration used. For 3 µM protein the slits were 10 and 20 
mm for excitation and emission, respectively. At the end of the measurements, 11 µM of BPTI were 
added to the wells containing 40 µM compound and the fluorescence was re-measured. Binding curves 
were analyzed according the following two-state model describing the formation of a 1:1 complex: 
PLLP
Kd
→←+  
The corresponding binding equation is  
 
Pt
PtLtLtPtKdLtPtKd
AmpOffsetSignal
.2
.4)()(
.
2
−++−++
+=  Equation 2 
where KD is the equilibrium dissociation constant, Pt and Lt are the total protein and ligand 
concentrations, respectively, and Amp is the amplitude of the measured response. This equation was 
used to analyze the binding isotherms. The data were fitted using the non-linear least square option of 
the GraphPad Prism software. 
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Isothermal Titration Calorimetry. Calorimetry experiments were performed with a Auto-ITC 
microcalorimeter (Microcal). All titrations were done at 25 oC. For standard experiments, 6 µM of 
NS2B/NS3 protease was titrated with 10 µl injections of 80 µM BPTI. Each titration comprised an 
initial 1 µl injection. The stirring speed used was 300 rpm, and the reference power was 10 µcal/sec. The 
heat of the last injection of each titration series was subtracted from the titration data to account for the 
heat of dilution. For competition experiments, compounds were added to the protein in the cell. DMSO 
was added to the BPTI solutions in the syringe to obtain equal DMSO concentrations in the cell and in 
the syringe. KD values of the compounds from competition experiments with BPTI were estimated using 
the relationship(27) 
BPTID
compoundD
BPTID
apparentD ]Compound.[ −
−
−
−
+= K
K
K
K   Equation 3 
where 
compoundD−K is the true KD value for the protease-compound association, PTIK BD −  is the KD for the 
protease-BPTI association in the absence of compound and apparentD−K is the apparent KD for protease-
BPTI association in the presence of compounds. 
 
SPR biosensor measurements. Measurements were done on a Biacore 3000 instrument (Biacore, 
Uppsala, Sweden). DEN2 CF40-gly-NS3pro186 with a C-terminal Cys residue was immobilized via the 
engineered cysteine to a level of 7000RU on a carboxymethyl-dextran sensor surface (CM5) using 
ligand-thiol coupling chemistry, according to the following procedure, where each step was performed 
sequentially at a flow rate of 10 µl/min: (i) 7-min injection of a mixture of 0.1 M NHS and 0.4 M EDC, 
(ii) 3-min injection of 80 mM PDEA, (iii) 3.5-min injection of 1.0 M ethanolamine-HCl, (iv) 5-min 
injection of CF40-gly-NS3pro186 in sodium acetate, pH 4.0, (v) 7-min injection of 50 mM cysteine in 1 
M NaCl. The control surface was treated in an identical way, omitting the injection of the protein. The 
inhibitors were diluted with 50 mM phosphate buffer, pH 7.4, and 5% DMSO (final concentration). The 
same buffer was used as running buffer throughout the experiment. 0.078 to 12.5 µM inhibitors were 
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injected for 1 min sequentially over the reference and test flow-cells at a flow rate of 30 µl/min. Raw 
sensorgrams were reduced and solvent-corrected using a DMSO calibration curve(28, 29) using the 
Scubber software package (BioLogic Software, Campbell, Australia). Binding affinities were evaluated 
by fitting the data to the 1:1 Langmuir and steady-state models using Biaevaluation 4.1.  
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RESULTS 
HTS/Choice of Lead Compound/Structure of Inhibitor. We previously reported the development of a 
highly sensitive and robust in vitro assay using the substrate, Bz-nKRR-AMC, for monitoring dengue 
single-chain NS2B/NS3 protease activity(26). The assay was used to test peptidic inhibitors against 
DENV and WNV proteases(17, 19, 20),25. We adapted it into a 1536-well format and used it to screen 
our in-house library comprising approximately 106 compounds. One class of compound was observed to 
inhibit DENV2 and WNV proteases with IC50 values of 2 and 3 µM respectively. However, this 
compound class and its synthetic intermediates were highly insoluble and the synthesis and testing of 
analogues proved to be challenging (data not shown).  
A preliminary search for structurally related compounds yielded a second compound, 1, with a more 
readily amenable scaffold (IC50 for DENV and WNV = 6 and 24.5 µM respectively; Figure 1). Binding 
of 1 to the catalytic pocket was verified by NMR spectroscopy, where the presence of 1 led to a 
dramatically improved 15N-HSQC spectrum of the DENV2 protease (Figure S1). Although, in the 
absence of resonance assignments of the protease, this does not prove binding of 1 to the catalytic 
pocket, the same observation was made in 15N-HSQC spectra of the WNV protease. For the WNV 
protease, NMR resonance assignments are available and intermolecular NOEs showed that 1 binds to 
the catalytic pocket (Su et al., manuscript submitted).  
We subsequently initiated chemistry efforts using compound 1 as lead compound with the goal to 
generate a more potent DENV protease inhibitor. In addition, in the absence of a crystal structure of 
DENV protease-inhibitor complex, binding mode of compound 1 was obtained by automatic docking 
with a suite of programs SEED/FFLD and CHARMM minimization(30-33; Figure 2A) using the 
structure of WNV protease bound with a tetrapeptide aldehyde inhibitor Bz-nKRR-H(34). The central 
phthalazine ring is located in a cavity of S1 pocket and forms π-π interaction with the phenyl group of 
Tyr161. Both charged imidazoline groups are involved in salt bridge or hydrogen bonds with several 
residues (Asp129, Gly159 and Asn84). Furthermore, one of the NH group linking the phenyl and 
phthalazine moieties forms a hydrogen bond with Pro131 backbone carbonyl oxygen. These results are 
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in agreement with intermolecular NOEs reported for the homologous compound 5 (Su et al., manuscript 
submitted). 
The predicted binding mode of compound 1 in the protease catalytic site (Figure 2A), as well as 
quantum-mechanical calculations to determine the lowest-energy state of compound 1 and derivatives 
thereof, were used to design more analogues.  
Based on these data, about 130 compounds were subsequently synthesized. Several analogues 
inhibited DENV and WNV proteases at IC50 values in the low micromolar range (representative 
compounds are shown in Tables 2 and 3). Yet, despite extensive efforts, none of the analogues 
synthesized possessed sub-micromolar inhibitory activities and no clear SAR emerged from these 
studies. It is not unusual that micromolar leads with unfavorable physical properties (e.g. solubility) 
show flat SAR and turn out to be unsuitable for lead optimization. In this case, however, we had clear 
evidence that the lead compound was binding to the target protein and therefore the absence of SAR was 
puzzling. 
 
IC50 values for different DENV serotypes. To expand our understanding of the inhibitory properties of 
this class of compounds, we tested a subset on proteases from the four different dengue serotypes 
(DENV1, 2, 3 and 4). NS2B/NS3 proteases from DENV1-4 share between 50-70% sequence identity(35) 
and NS3 amino acid residues forming the substrate binding pockets S1, S2 and S3 are mostly 
conserved28. Differences between the catalytic pockets of DENV1-4 arise from non-conserved NS2B 
amino acid residues that participate in formation of S2 and S3 pockets31. These variations could 
conceivably alter the binding affinities of inhibitors, by changing the NS2B structure or its ability to re-
organize upon ligand binding(34). Indeed IC50 values obtained with the peptidic inhibitor Bz-nKRR-H, 
varied from 1.4 to11.8 µM across DENV1-4 (Table 2). This is in line with our previous finding that 
despite similar preferences for P1-P4 residues in substrate sequences, their overall catalytic efficacies 
are not the same(26). 
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Amongst several structurally similar compounds, we found two different types of behaviors. One 
group, represented by inhibitors 1, 3, 5 and 8 showed selectivity amongst the different proteases with 
inhibition curves that exhibited Hill slopes ranging from 1-2. The second group represented by 
compounds 2 and 7 had similar inhibitory effects on different proteases and consistently displayed Hill 
slopes much larger than 1 (Table 2), suggesting that they act as non-specific inhibitors. Compounds 4, 6 
and 9 were control compounds that were poorly or non-inhibitory (Table 2).  
 
Tryptophan Fluorescence. DENV2 NS2B/NS3pro contains five tryptophans (W5, W50, W69, W83, 
W89) in the NS3pro moiety and one tryptophan in the NS2B co-factor (W23). Since no 3D structure of 
DENV2 NS2B/NS3pro in complex with a ligand is available, Figure 2B illustrates the locations of the 
trytophan residues in the structure of the homologous WNV NS2B/NS3pro (PDB accession code 
2FP7(34)). All tryptophan residues of DENV2 NS2B/NS3pro are also present in WNV 
NS2B/NS3pro(34). None of the tryptophans is in the protease catalytic pocket and the model of the 
complex with compound 1 suggests the absence of any direct contacts between 1 and any of the 
tryptophan residues. Nonetheless, to test whether tryptophan fluorescence can be used to monitor 
compound binding, we utilized 1 as a reference compound. The absorbance spectrum of 1 has two main 
absorption bands at 300 and 380 nm and overlaps with tryptophan emission, usually at 305-360 nm 
(Figure 3). When bound to the protease active site, compound 1 can potentially influence the 
fluorescence of the nearby tryptophans by a Förster resonance energy transfer (FRET). Since 1 has 
negligible intrinsic fluorescence (data not shown), its binding can be followed by monitoring the 
decrease in fluorescence signal intensity of the tryptophan residues. 
 
Binding of compound 1. We titrated 4 µM DENV2 NS2B/NS3pro with 1 (from 0 to 40 µM) and 
monitored fluorescence emission at 340 nm (excitation at 280 nm). Addition of 1 led to fluorescence 
quenching of the tryptophans in the protease (Figure 4A). The effect was not caused by a change in the 
environment of the tryptophan side chains, as their emission wavelength maximum (λmax) remained 
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unchanged. A plot of fluorescence intensity versus inhibitor concentration showed a classical binding 
isotherm (Figure 4B). Nevertheless, the observed shallow shape of the binding isotherm indicated that 
the protein concentration used was comparable to or below the KD value of the inhibitor, thus preventing 
a good estimate of binding stoichiometry. Therefore, 1:1 binding stoichiometry was assumed for all fits 
to allow comparison between different compounds. The KD value obtained for 1 was 6 ± 2.6 µM and is 
comparable to its IC50 value obtained in the enzyme assay (Table 2). 
Binding of 1 to NS2B/NS3pro catalytic pocket was further proven by using bovine pancreatic trypsin 
inhibitor (BPTI or aprotinin)(36), which is a known competitive ligand of the protease. BPTI did not 
induce any fluorescence change upon binding to the protease (data not shown). When BPTI was added 
to wells containing DENV2 NS2B/NS3pro and compound 1, we observed an increase of fluorescence 
(Figure 4B). This indicates that BPTI can displace the binding of 1, and confirms that the latter binds in 
the same pocket as BPTI. Competitive binding was also observed with the peptidic inhibitor Bz-nKRR-
H (34) (data not shown). 
 
Which Tryptophan is targeted in the quenching experiments? In order to decipher which tryptophan 
residue was targeted by the quenching experiments, we systematically mutated the five tryptophan 
residues of DENV2 NS3pro (W5, W50, W69, W83, W89) to alanine and titrated the mutant proteins 
with compound 1. Normalized titration curves revealed that the mutants and WT showed similar KD 
values for 1 ranging from 5-8 µM (Figure 4C), with the exception of the W83A mutant (not shown). The 
crystal structures of DENV and WNV proteases show that W83 is buried, suggesting that W83A 
mutation destabilizes the protein structure. W83A was also the least active mutant, with only 1% of the 
WT activity (data not shown). Thus the role of W83 in the fluorescence studies could not be accurately 
assessed. 
In contrast, the other mutants allowed us to pinpoint tryptophan residues affected by inhibitor binding. 
Most of the fluorescence change from binding of compound 1 could be attributed to W50 as mutating 
this residue to alanine resulted in the greatest loss in fluorescence intensity (Figure 4C). This is not 
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surprising since W50 is in direct proximity of the binding site(34) (residue H51 is part of the catalytic 
triad). Thus, the titration experiment with W50A further ascertained that 1 was binding to the catalytic 
pocket. W69 and W89 are also involved in compound induced FRET as mutating these to alanine 
likewise resulted in significant loss in fluorescence signal. In contrast, fluorescence was unchanged in 
W5A, implying that this residue plays a negligible role in the signal change. 
 
Compounds binding to DENV2 protease. For SAR analysis, fluorescence titrations were performed 
with 63 compounds. Some representative absorbance spectra of the compounds are shown in Figure 3. 
Since the parent compound 1 had the optical properties required to quench tryptophan fluorescence, 
most of the structurally related analogues (all bearing the central phthalazine rings) from the SAR study 
had the same property. Six of these titrations are represented in Figure 5A and the KD values obtained 
are listed in Table 3. These compounds spanned a wide range of IC50 values (from 1 to 55 µM; Table 3). 
To our surprise, only one out of four compounds with good IC50 values showed good binding (3, IC50 = 
1.1 µM, KD = 7.7 µM). The binding affinity of 3 was similar to 1, despite 5-fold difference in their IC50 
values. Of the remaining three compounds, one showed intermediate binding (5, IC50 = 5.8 µM, KD = 
18.6 µM) whilst two were poor binders (2, IC50 = 2.3 µM, KD = 100 µM and and 7, IC50 = 1.6 µM, KD = 
100 µM). Titration of these compounds with BPTI resulted in displacement of 3 and 5 only, indicating 
that only these compounds are competitive binders and not compounds 2 and 7. These results are in 
agreement with the steep Hill slopes observed in the inhibition curves of DENV 1-4 proteases for the 
latter two compounds. On the other hand, KD values for two compounds that showed intermediate 
binding (4, and 8, KD = 22.9 and 16.3 µM respectively) correlated well with their IC50 values and 
likewise, two poorly inhibitory compounds (6 and 9; IC50 = 55 and >100 µM) were also found to be 
weak or non-binders. When BPTI was added to the wells after each titration, competition was observed 
for compounds 4, 6, and 8, but not 9, demonstrating their different binding specificities.  
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Compounds binding to WNV protease. WNV and DENV proteases are homologous proteins but show 
different sensitivity towards different compounds. For example, compound 6 displayed a relatively low 
IC50 value for WNV protease (6.2 µM) but not for DENV2 (55 µM; Table 3). This raised the question 
whether the tryptophan fluorescence assay would detect these differences. The same fluorescence 
quenching experiments can be applied for WNV and DENV proteases since tryptophans are present in 
both proteins at the same positions. We titrated WNV with the compounds as before and obtained a KD 
value for compound 1 that was similar to its IC50 value (Figure 5B; Table 3). Interestingly, two 
compounds which were weak inhibitors and binders to DENV2 protease displayed good IC50 values and 
good binding affinities to WNV protease (compounds 4 and 6; KD = 4.6 and 7 µM, respectively). 
Conversely, some of the compounds which were more potent against DENV than WNV, bound only 
weakly to the WNV protease and showed poor KD values for the latter (compounds 3 and 5, KD= 90 and 
100 µM respectively). Finally, compounds 2 and 7 which showed comparable IC50 values in DENV2 
and WNV, also bound poorly to WNV (KD = 100 µM). 
 
Isothermal Titration Calorimetry. ITC was used to corroborate the binding affinities obtained by 
tryptophan fluorescence. Due to low compound binding affinities and low solubilities, no satisfactory 
data were obtained in ITC experiments where the compounds were directly titrated to the DENV2 
protease. To circumvent this experimental barrier, we performed competition ITC using BPTI. Titration 
of 6 µM protease with 80 µM BPTI resulted in exothermic binding and gave KD = 19 nM, n = 1.19 and 
∆H = -5.5 kcal/mol (Figure 6). Competition experiments were performed by titrating the protein-BPTI 
complex with different compounds. Figure 6 shows representative examples of titrations performed with 
compounds 3, 8, and 9. Compound 9 was used as a control since it did not inhibit the protease activity 
and did not show any binding to the protease by fluorescence (Table 3). Addition of 100 µM of 
compound 9 did not induce any significant change on the apparent KD or the binding enthalpy of BPTI 
(30 nM and -5.4 kcal/mol). In contrast, 100 µM compound 3, and 150 µM compound 8 resulted in the 
respective changes in BPTI binding: KD = 125 nM and ∆H = -3 kcal/mol, and KD= 77 nM and ∆H= -2.6 
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kcal/mol. Other compounds were also tested for competition by ITC (Table 3). In summary, based on 
changes observed in the apparent KD and/or on the binding enthalpy for BPTI, compounds that clearly 
competed with BPTI binding were: 1, 3, 5, and 8 whilst non-competing compounds were 2 and 9. 
Results from ITC experiments concurred with the previous fluorescence quenching data as compounds 1, 
3, 5 and 8 were identified as specific protease binders. Conversely, compounds which showed no 
binding in fluorescence are also negative in ITC (2, 7). 
Surface plasmon resonance. Binding affinities between compounds 1, 2, 3, 5, 8, 9 and DENV2 
protease were evaluated using an SPR biosensor. DENV2 protease was immobilized on the matrix via 
an engineered C-terminal cysteine and increasing concentrations of compounds were passed across 
(from 78 nM to 12.5 µM). The results are summarized in Table 3. Generally, the compounds showed 
fast on- and off-rates in this concentration range. Compounds 1 and 8 gave satisfactory sensorgrams 
allowing a straightforward analysis. Binding affinity for compound 1 was evaluated by fitting the data to 
the 1:1 Langmuir (Figure S2) and steady-state models (data not shown), which returned similar KD 
values of 3.75 µM and 2 µM, respectively. However, at concentrations above 12.5 µM, we observed 
deviations from the 1:1 fit presumably due to non-specific binding to the immobilized protein or 
carboxy methyl matrix. A competition assay showed that BPTI completely displaced 1 from its binding 
site on the protease (Figure S3). This corroborated with results from other biophysical methods tested 
that compound 1 shares part of the binding site of BPTI. 
Following steady-state model, compound 8 yielded a KD value of 4.3 µM. Compounds 2, 3, 5 and 9 
displayed evidence of non-specific interactions. Following addition of 150mM NaCl to the phosphate 
buffer, specific binding was observed for 3 (KD = 0.3 µM), but not for compound 5 (KD = >100 µM). 
Non-specific binding persisted for compounds 2 and 9. 
 
DISCUSSION 
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This study highlights the importance in drug discovery to confirm IC50 measurements with binding 
assays. The tryptophan fluorescence quenching assay presented here provided information on the 
binding mode of the compounds, including their binding site and the tightness of association. Using this 
assay, we systematically measured the binding affinities of 63 compounds generated from the SAR 
study and compared the KD values obtained with their IC50 values (date not shown).We observed that in 
a number of instances, small modifications of compound structures led to dramatic changes in 
specificity of inhibition. These changes were not always detectable by IC50 measurements. Nine key 
compounds were further characterised and are presented in this report. 
Tryptophan fluorescence quenching. Our experiments revealed that the change in tryptophan 
fluorescence upon protease-compound binding was caused by a FRET mechanism where the compounds 
acted as tryptophan fluorescence acceptors. Binding of compounds did not induce any apparent 
conformational changes in the immediate vicinity of tryptophan side chains as no change in emission 
maximum was observed (Figure 4A). Our studies with Trp-to-Ala mutants showed that fluorescence 
change induced upon compound binding was mostly due to W50 in the NS3 moiety. W50 is the 
tryptophan nearest to the active site, and in the co-complexed WNV protease-Bz-nKRR-H crystal 
structure (34), the C-α distance between W50 and the center of the peptide is about 10-15 Å. Is this 
distance sufficiently short for a FRET? Förster distances FR (where FR corresponds to the distrance 
where 50% FRET efficacy is observed) of 6-12 and 21 Å have been reported for Trp-Trp homo-transfer 
and Trp-Dansyl pairs(37), respectively. As the distance between W50 and the compound falls within this 
range, the significant FRET observed is fully expected.  
A potential pitfall associated with fluorescence spectroscopy is the inner filter effect (IFE) which 
arises when the absorbance of the sample becomes too high at the excitation and emission wavelengths. 
IFE causes a non-linearity of the fluorescence signal which can be estimated by  
210.
emexc AbsAbs
obs FF
+
−
=  Equation 1 
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where Fobs is the measured fluorescence, F is the fluorescence after IFE correction, and Absexc and 
Absem are the absorbance at the excitation and emission wavelength, respectively(38). The compounds 
tested in this study absorbed both at 280 and 340 nm so that, in principle, IFE could have contributed to 
the signal change observed. A control experiment where 15 µM solutions of N-acetyl-tryptophanamide 
were titrated with four of the compounds showed, however, that IFE is only minimally responsible for 
the fluorescence decrease (Figure S4). Therefore the hyperbolic shapes observed in the titration 
experiments of the protease were indeed due to specific binding. 
 
Correlation between IC50values and specific binding. Our goal in developing the TRP-fluorescence 
binding assay was to screen out non-specific inhibitors and to ascertain if compounds were binding 
competitively to the enzyme. A total of 63 compounds were tested in our study for their inhibitory 
capabilities (IC50) and their binding affinities (KD). This approach identified promiscuous inhibitors and, 
using BPTI, we demonstrated that only a subset of compounds with low KD were truly competitive 
binders (data not shown). On the other hand, attempts to eliminate non-specific binders by addition of 
Triton-X-100 in the enzyme assay was not very successful, as even the reference inhibitor, Bz-nKRR-H, 
showed at least five-fold change in IC50 values in the presence of the detergent (data not shown). 
Compound 1, which was the parental compound from which SAR was developed, showed comparable 
IC50 (6±2.6 µM) and KD values from Trp fluorescence (7.5±3.2 µM) and ITC (7.3 µM) as well as SPR 
(3.75 µM) for DENV2 protease. We further observed competition of 1 with BPTI by ITC, SPR and 
fluorescence quenching. NMR experiments confirmed that it interacted with the DENV2 protease active 
site (Figure S1). Compound 1 showed some differences in affinities for different dengue serotypes (IC50 
value varied between 6 µM for DENV2 and 33 µM for DENV4) and the Hill slopes obtained were close 
to 1, indicating a specific mode of inhibition(7, 39). The same is true for compounds 3 and 8. 
On the other hand, compound 2 displayed one of the best IC50 values in our SAR analysis (2.64±0.44 
µM for DENV2 protease). Despite its potency, no binding was detected by Trp fluorescence and 
addition of BPTI after the titration did not induce any decrease in fluorescence intensity. This was 
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confirmed by ITC where no competition with BPTI was observed and again by the absence of binding in 
SPR. Hence it is likely that compound 2 is a non-specific inhibitor. This reasoning also applies to 
compound 7. Careful inspection of the enzyme inhibition data for WNV and DENV1-4 proteases 
revealed two variables as particularly useful criteria of specific binding. Firstly, the inhibition curves 
obtained with 2 and 7 displayed steep transitions. This translated into steep Hill slopes which strongly 
suggested that they act by a non-specific mechanism(7, 39). Relying solely on Hill slopes, however, may 
be misleading. For example, compounds 3, 5 and 8 gave Hill slopes of about 2 (Table 2), yet data from 
fluorescence quenching experiments and ITC clearly showed that they were specific inhibitors. These 
examples reinforce our conclusion that it is important to use a repertoire of biochemical and biophysical 
techniques to accurately determine compound binding specificity during drug screening. 
Secondly, IC50 values obtained with compounds 2 and 7 were very similar for WNV and DENV1-4, 
indicating that they inhibited all proteases equally well. This is unexpected considering that the S1 site 
of WNV protease catalytic pocket differs from those of DENV1-4 proteases and NS2B residues forming 
S2 and S3 sites are also not well conserved between WNV and the different DENV serotypes. Moreover, 
the transition state analogue Bz-nKRR-H showed different inhibition properties with proteases from the 
different dengue serotypes (Table 2) and WNV(17). We conclude that in the present SAR, similar IC50 
values observed for the different serotypes, coupled with high Hill slopes, indicated non-specific 
inhibition.  
 
Use of tryptophan fluorescence for drug discovery. The tryptophan fluorescence assay presented here 
proved to be a very useful tool for our drug discovery effort as it discriminated between specific and 
non-specific compounds from our SAR study. The method has many advantages. Firstly, small amounts 
of purified recombinant proteins can be readily used without need for further labeling or tagging. 
Secondly, fluorescence spectroscopy tolerates a wide range of buffer conditions, salts, detergents, or 
reducing agents. Thirdly, the binding assay can be done in 96- or 384-well formats. Automation would 
further increase throughput. Fourthly, the sensitivity of this method allows measurements of KD values 
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in the range from 0.1 to 20 µM. Below 0.1 µM, the shape of the binding curve would not permit a 
precise determination of the KD value whereas above 20 µM, inner filter effect would obscure 
fluorescence decrease induced by ligand-protein binding. Assays sensitive to this range of KD values are 
of great value in the critical drug discovery phases of hit-to-lead conversion and early lead optimization. 
 
Comparison with other biophysical methods. As described in this manuscript, we also explored other 
biophysical techniques besides tryptophan fluorescence to evaluate the binding characteristics of 
compounds from our SAR study. The major issue we encountered was low compound solubility which 
prevented meaningful analysis by NMR and ITC. Consequently these methods offered a mostly 
qualitative observation (binding or no binding), whilst quantitative binding parameters (rather than 
binary answers) are paramount for understanding SAR. Another drawback of these techniques is that 
compounds that are poorly soluble at high concentrations will be eliminated in the studies even if they 
are specific inhibitors. With SPR, we observed a correlation with KD measured by fluorescence for most 
of the compounds, except for compound 5. We don’t know the reason for this discrepancy. The 
compound could have aggregated from non-specific interactions with the immobilized protease or chip 
matrix. 
In contrast, we rarely faced solubility or aggregation problems in the fluorescence quenching assay 
with the concentrations of compounds tested (up to 40 µM) and were able to quantify the binding 
affinities of most specific compounds. 
 
CONCLUSION 
As tryptophans are present in most proteins, the Trp fluorescence quenching assay presented here is 
applicable to other studies of protein-compound interaction. If Trp residues are absent or far from the 
binding site, they may be introduced by site-directed mutagenesis. The simplest manner to detect 
compound binding is via direct compound quenching of tryptophan fluorescence as shown in this report 
or by observing changes in trytophan emission maximal. Most compounds in drug discovery follow the 
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Lipinski rules(40) and are largely hydrophobic, often aromatic, molecules. Absorbance spectra of such 
compounds often span the spectral range from 270 to 400 nm, making them suitable quenchers of 
tryptophan fluorescence. In the case where a class of compounds lack these spectroscopic properties, a 
known inhibitor that induces a fluorescence change upon binding could be used as a competitor. The 
ease of implementing this technique makes it well suited for drug discovery needs.  
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Table 1. Examples of techniques used to measure binding. 
Methods Cost Throughput Specificity 
ITC High Low Yes 
X-Ray Very High Very Low Yes 
Nuclear Magnetic Resonance Very High Low Yes 
Thermal shift Low High No 
Biacore Medium High Yes 
 
 
Table 2. IC50 values and Hill slopes obtained with different compounds and proteases (DENV1-4).  
Compound DENV1 DENV2 DENV3 DENV4 
 IC50 
(µM) 
Hill 
Slope 
IC50 
(µM) 
Hill 
Slope 
IC50 
(µM) 
Hill 
Slope 
IC50 
(µM) 
Hill 
Slope 
1 36.4 1.0 6.0.6 0.8 17.5 0.9 32.8 0.9 
2 2.0 2.4 2.3±0.6 5.1 1.6 3.9 2.0 5.6 
3 10.7 1.8 1.1±0.2 0.4 8.5 1.1 13.6 1.6 
4 233 1.4 27.4 0.9 100 0.9 64.8 1.3 
5 12.3 2.4 5.8±2.3 1.6 8.7 1.4 8.2 2.3 
6 170 0.9 55 0.5 86 0.7 43 1.3 
7 2.72 2.64 1.6±0.8 3.2 1 3.3 1.3 5.2 
8 21.4 1.8 10.2±6 0.9 27.9 1.2 19.8 2.4 
9 >100 NA >100 NA >100 NA >100 NA 
Bz-nKRR-H 11.8±0.9 1.05 8.9±0.5 1.06 7.9±3 1.15 1.4±0.5 0.80 
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Table 3. IC50 and KD values of different compounds for DENV2 protease and WNV protease.  
Compound  DENV2 
IC50 (µM) 
DENV2 KD, 
µMa 
DENV2 
Competition 
ITCb 
DENV2 
KD (µM) 
by ITCc 
DENV2 
KD (µM) 
by SPR 
WNV 
IC50 
(µM) 
Hill 
Slope 
WNV 
KD 
(µM)  
1 6±2.6 7.2±3.2 (Y) Y 7.3 3.7 24.5 3.5 21 
2 2.3±0.6 100 (N) N N NB 3.6±1.8 2.6 100 
3 1.1±0.2 7.7±2 (Y) Y 13 0.3 22 1.4 90 
4 27.4 22.9 (Y) nd nd nd 5.2 1.0 4.6 
5 5.8±2.3 18.6 (Y) Y 17 >100 10.6 1.9 100 
6 55 54 (Y) nd nd nd 6.2 1.1 7 
7  1.6±0.8 100 (N) N N nd 2.2 3 100 
8 10.2±6 16.3±0.3(Y) Y 40 4.3 16 2.0 nd 
9 >100 100 (N) N N NB nd nd nd 
 
aY(yes) and N(no) indicates whether competition was observed or not between compound and BPTI. 
b“Competition ITC” reflects a qualitative judgment of the competition data based on both change in 
KD and change in binding enthalpy. Y and N indicates whether competition was observed or not 
between compound and BPTI. 
cFor compound 1, the KD value was calculated based on a single concentration of compound 1 while 
the KD values for compounds 3 and 8 were determined from several compound concentrations using 
equation 1. 
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FIGURE LEGENDS 
Figure 1. Structures of phthalazine-based compounds. The central phthalazine ring is shown on the left. 
Compounds are numbered from 1-9 where 1 represents the parental compound and 2-9 are 
representative modified derivatives described in the report. 
Figure 2. Binding of compound 1 in WNV NS3/NS2B protease obtained by automatic docking with 
FFLD and CHARMM minimization. (A) Close up view of WNV NS3/NS2B in complex with 
compound 1. The protein surface (PDB code 2FP7) is colored according to atomic partial charges. 
Compound 1 is colored by atom type and the nonpolar hydrogens is not shown for clarity. The central 
phthalazine ring is located in a cavity of S1 pocket and forms π-π interaction with the phenyl group of 
Tyr161. Both charged imidazoline groups are involved in salt bridge or hydrogen bonds with several 
residues (Asp129, Gly159 and Asn84). One of the NH group linking the phenyl and phthalazine 
moieties forms a hydrogen bond with Pro131 backbone carbonyl oxygen. (B) Location of trytophan 
residues in WNV NS2B/3 protease. Binding pose of compound 1 is shown by green sticks. NS2B is 
depicted as blue ribbons and NS3 as red ribbons. Tryptophan residues are represented as yellow sticks 
and are labeled. The catalytic triad and the conserved residues of NS3 at the S1, S2, and S3 sites are 
colored in magenta. The figures were made using PyMOL (http://pymol.sourceforge.net/). 
Figure 3. Absorbance spectra of 100 µM compounds measured on a 96-wells plate. Compound numbers 
are indicated in the figure. 
Figure 4. Titration of DENV2 protease with compound 1. (A) Fluorescence spectra of DENV2 protease 
at varying protein concentrations. The kinks in the spectra at 400 nm are an artifact of the microplate 
reader. (B) Titration of WT DENV2 protease with compound 1 monitored by fluorescence at 340 nm. 
The solid line is the fit of the data to equation 3. Symbol () shows the level of fluorescence reached 
after addition of 11 µM BPTI to the well containing WT protein and 40 µM compound 1. (C) Titration 
of WT and W mutants with compound 1. Normalized fluorescence at 340 nm (measured fluorescence (F) 
divided by the fluorescence measured in the absence of compound (F0)). The solid lines are the fit of the 
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data to equation 3. WT (), W5A (), W50A (), W69A (),W89A (). Following the same order, 
the resulting KD were: 4.7, 5.15, 6.2, 6.6, and 7.8 µM.  
Figure 5. Fluorescence titrations performed with several compounds. Titration data were normalized by 
dividing the measured fluorescence (F) by the fluorescence measured measured in the absence of 
compound (F0). (A) Titration of DENV2 protease; (B) Titration of WNV protease. Solid lines show the 
fit of the data to equation 3. Titrations with different compounds are represented as follows:, 1 (), 2 
(), 3 (), 4 (),.5 (), 6 (), 7 (). 
Figure 6. ITC Competition Titration. Titrations of 6 µM DENV2 protease with 28 consecutive 10 µl 
injections of 80 µM BPTI at 25 oC were performed in the presence of varying concentrations of 
compounds. Typical titrations are shown in the absence of compound () and in the presence of 150 
µM compound 8 (), 100 µM compound 3 (), and 100 µM compound 9 (). 
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SUPPORTING INFORMATION AVAILABLE 
Oligonucleotide sequences of mutagenesis primers, 15N-HSQC spectra of DENV2 protease with and 
without compound 1, SPR studies of the binding of compound 1 and titration of N-acetyl-
tryptophanamide with compounds, chemistry and compound syntheses. This material is available free of 
charge via the internet at http://pubs.acs.org. 
 
 
